Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imbruvica

- PMLiVE

AbbVie files patent infringement lawsuit against BeiGene’s blood cancer drug Brukinsa

The BTK inhibitor was approved in the US earlier this year and had its patent issued last week

- PMLiVE

AbbVie announces positive phase 3 results for Skyrizi in ulcerative colitis

Inflammatory bowel disease is estimated to affect nearly one in every 100 people in the US

- PMLiVE

AbbVie’s Rinvoq receives FDA approval for Crohn’s disease

Inflammatory bowel disease affects nearly one in every 100 people in the US

- PMLiVE

AbbVie and Genmab’s blood cancer therapy granted FDA accelerated approval

Approximately 150,000 new cases of DLBCL are diagnosed globally each year

- PMLiVE

AbbVie’s Rinvoq recommended by NICE for Crohn’s disease

It is estimated that over 155,000 adults are living with the condition in the UK

- PMLiVE

Janssen and AbbVie’s Imbruvica combination recommended by NICE for leukaemia

Approximately 3,800 people in the UK are diagnosed with chronic lymphocytic leukaemia each year

- PMLiVE

AbbVie’s Rinvoq approved by EC for Crohn’s disease

The therapy is now the first oral JAK inhibitor authorised to treat this patient population

- PMLiVE

AbbVie’s Parkinson’s disease therapy application rejected by FDA

The regulator has requested more information on the pump used to administer ABBV-95

- PMLiVE

AbbVie’s Rinvoq approved by MHRA for Crohn’s disease

Over 155,000 adults in the UK are estimated to have the disease, with 40% of them having moderate or severe symptoms

- PMLiVE

BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia

The BTK inhibitor demonstrated better results than Imbruvica, a standard of care treatment in CLL

- PMLiVE

BeiGene’s Brukinsa granted two new marketing authorisations by MHRA

The BTK inhibitor is now approved for chronic lymphocytic leukaemia and marginal zone lymphoma

- PMLiVE

AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement

Both companies will now come under the scheme imposed by the government through law

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links